The recent Medicare price of USD 322 is the latest progress during a quarter of improved commercial presence including Direct Bill, Hospital contracts, pharma partner projects and European distribution. Actual sales is in line with our expectations and Biovica reiterates the outlook including higher DiviTum test volumes during calendar H1 2024. Our updated Base Case reflects the ongoing Rights Issue priced at SEK 2.61 and our new Base Case is SEK 19 ( 27) with a Bull of SEK 45 (60) and a Bear case of SEK 2 (5).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Biovica - Approaching increasing recurring revenues

© Modular Finance, source Nordic Press Releases